標(biāo)題: Titlebook: Biologic and Systemic Agents in Dermatology; Paul S. Yamauchi Book 2018 Springer International Publishing AG 2018 systemic dermatology.bio [打印本頁] 作者: Encomium 時間: 2025-3-21 19:47
書目名稱Biologic and Systemic Agents in Dermatology影響因子(影響力)
書目名稱Biologic and Systemic Agents in Dermatology影響因子(影響力)學(xué)科排名
書目名稱Biologic and Systemic Agents in Dermatology網(wǎng)絡(luò)公開度
書目名稱Biologic and Systemic Agents in Dermatology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biologic and Systemic Agents in Dermatology被引頻次
書目名稱Biologic and Systemic Agents in Dermatology被引頻次學(xué)科排名
書目名稱Biologic and Systemic Agents in Dermatology年度引用
書目名稱Biologic and Systemic Agents in Dermatology年度引用學(xué)科排名
書目名稱Biologic and Systemic Agents in Dermatology讀者反饋
書目名稱Biologic and Systemic Agents in Dermatology讀者反饋學(xué)科排名
作者: 要素 時間: 2025-3-21 23:39
978-3-319-88337-3Springer International Publishing AG 2018作者: Spangle 時間: 2025-3-22 00:46
Paul S. YamauchiWritten by leading experts in the field for dermatologists and dermatology residents.Describes the mechanism of action of various systemic and biologic agents, as well as their clinical efficacy and s作者: 步履蹣跚 時間: 2025-3-22 04:50 作者: crescendo 時間: 2025-3-22 09:25 作者: 群居動物 時間: 2025-3-22 15:07
Kinderarmut und soziale Ausgrenzung in Polen effect of therapy, valid outcome measures are commonly employed in clinical trials and in clinical practice. The most commonly used in psoriasis clinical trials include the Psoriasis Area and Severity Index (PASI), the extent of body surface area involvement (BSA), and various physician or investig作者: 致敬 時間: 2025-3-22 17:35 作者: 遣返回國 時間: 2025-3-23 00:35 作者: needle 時間: 2025-3-23 03:16
https://doi.org/10.1007/978-3-322-92447-6ical functioning. The impact of these diseases on quality of life (QOL) can be significant, and the psychosocial impact of many dermatologic diseases is often more impactful than the physical appearance or symptoms alone. We now know that many chronic dermatologic conditions are more than skin deep,作者: tenuous 時間: 2025-3-23 09:08
Kinderarmut und soziale Ausgrenzung in Polenn reported and the warning labels have expanded. A variety of issues are now linked to biologic associated tumor necrosis factor-alpha (TNF-α) blocker use. Litigation has occurred with the use of a variety of biologics. The published risks of these agents include the development of lupus and autoimm作者: 雜色 時間: 2025-3-23 10:54 作者: eustachian-tube 時間: 2025-3-23 17:46 作者: 凝乳 時間: 2025-3-23 19:08
https://doi.org/10.1007/978-3-322-93540-3l are useful to determine short-term efficacy and side effects but with the relatively low numbers of patients may not provide realistic data on rare adverse events. In addition, a significant percentage of patients not eligible for clinical trials are placed on biologic therapy post-approval. Conti作者: aesthetician 時間: 2025-3-24 00:14
Kinderarmut in Ost- und Westdeutschlanderapies in dermatology. Understanding the basic principles of pharmacoeconomics and how they apply to dermatology is important for all dermatologists and medical trainees. In this chapter, we review the key concepts of pharmacoeconomics and give examples of these as they pertain to systemic therapy 作者: Defense 時間: 2025-3-24 05:38 作者: harbinger 時間: 2025-3-24 08:00
Von der Nachkriegsnot zur Familienpolitik, thus the manufacturing of biologics is a complex process. This chapter discusses the multistep approach used to manufacture biotechnology-derived biologics. The chapter also discusses biosimilars and the complexity of their development and manufacturing along with highlighting the differences betwe作者: jocular 時間: 2025-3-24 12:50 作者: micronutrients 時間: 2025-3-24 16:44
Kinderarmut in der Wohlfahrtsgesellschaft2]. CD4+ T helper cells, called T helper (Th) 17 cells, are important in the pathogenesis of psoriasis [2–5]. Interleukin (IL)-23 stimulates survival and proliferation of Th17 cells and thus serves as a key upstream cytokine regulator for this disease. Within psoriatic skin lesions, IL-23 is overpro作者: 十字架 時間: 2025-3-24 20:37
Hedi Colberg-Schrader,Ingrid Kurznot been fully elucidated, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease. The recent discovery of a set of pathogenic T cells that produce high levels of interleukin-17 in response to interleukin-23 led to a major paradigm shift in the pathogenic mode作者: 脊椎動物 時間: 2025-3-25 02:32
Einleitung: Kinderarmut und Bildungd indeed pocketbook [1–4]. Moderate-to-severe psoriasis has also been associated with multiple comorbidities including the metabolic syndrome, cardiovascular disease, depression, and psoriatic arthritis [5–9] (Fig. 16.1). For patients with moderate-to-severe psoriasis (>10% body surface area involve作者: 仲裁者 時間: 2025-3-25 07:02 作者: 破譯 時間: 2025-3-25 08:30 作者: 河潭 時間: 2025-3-25 14:41
Christoph Butterwegge,Michael Klundtription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders. Targeted JAK inhibitors (Jakinibs) are already in clinical use for rheumatoid arthritis, myelofibrosis, and polycythemia vera. These recent developments have spurred furth作者: Crohns-disease 時間: 2025-3-25 16:44
https://doi.org/10.1007/978-3-322-93540-3 for biologic therapy is very favorable. There has not been an increase in malignancy and major adverse cardiovascular events (MACE). Although no new safety signals were identified from analysis of registry information, a possible higher risk of serious infections was reported for patients taking adalimumab and infliximab.作者: 北極熊 時間: 2025-3-25 19:59
Im Schatten des Wirtschaftswachstums,which result in widely different results when measured. In this chapter we review the underpinnings of the development of immunogenicity, how it is measured, and how it may influence the success of biologic therapy. Additionally, we give a brief review of what is known about the immunogenicity of available biologic therapies for psoriasis.作者: Unsaturated-Fat 時間: 2025-3-26 02:26
Hedi Colberg-Schrader,Ingrid Kurzde for the treatment of other inflammatory skin conditions is not entirely clear, though early studies suggest that this class of medications represents a promising treatment strategy for several noninfectious lymphocytic and neutrophilic dermatoses, such as Sweet syndrome, Beh?et disease, and atopic dermatitis.作者: Individual 時間: 2025-3-26 08:18
Einleitung: Kinderarmut und Bildungn therapy for disease control. Collectively, nail, scalp, and palmoplantar psoriasis are considered “tough to treat” and often do not respond as well as plaque psoriasis elsewhere on the body. This chapter critically addresses the challenges posed by each condition and evaluates available treatment options.作者: Generic-Drug 時間: 2025-3-26 08:57
Christoph Butterwegge,Michael Klundtowing that Jakinibs have the potential to become a significant alternative medication class for cutaneous autoinflammatory disorders. This review will present an overview of this novel drug class, the mechanics of the signaling pathway, and clinical data in support of its therapeutic benefit.作者: angiography 時間: 2025-3-26 16:07
Pharmacovigilance, for biologic therapy is very favorable. There has not been an increase in malignancy and major adverse cardiovascular events (MACE). Although no new safety signals were identified from analysis of registry information, a possible higher risk of serious infections was reported for patients taking adalimumab and infliximab.作者: BALE 時間: 2025-3-26 19:25
Immunogenicity of Biologic Agents in Psoriasis,which result in widely different results when measured. In this chapter we review the underpinnings of the development of immunogenicity, how it is measured, and how it may influence the success of biologic therapy. Additionally, we give a brief review of what is known about the immunogenicity of available biologic therapies for psoriasis.作者: CAMP 時間: 2025-3-26 22:24
Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease,de for the treatment of other inflammatory skin conditions is not entirely clear, though early studies suggest that this class of medications represents a promising treatment strategy for several noninfectious lymphocytic and neutrophilic dermatoses, such as Sweet syndrome, Beh?et disease, and atopic dermatitis.作者: Nmda-Receptor 時間: 2025-3-27 05:00
Nail, Scalp, and Palmoplantar Psoriasis,n therapy for disease control. Collectively, nail, scalp, and palmoplantar psoriasis are considered “tough to treat” and often do not respond as well as plaque psoriasis elsewhere on the body. This chapter critically addresses the challenges posed by each condition and evaluates available treatment options.作者: GUILE 時間: 2025-3-27 06:42 作者: 用手捏 時間: 2025-3-27 09:46
Book 2018orders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis..作者: 增減字母法 時間: 2025-3-27 14:25
Kinderarmut und soziale Ausgrenzung in Polenune-like syndromes, squamous cell cancer (SCC), histoplasmosis, and coccidioidomycosis. This chapter focuses on litigation related to the use of biologics in dermatology, approaches to reducing physician liability, and hypothetical lawsuits against a dermatologist using biologics.作者: 使饑餓 時間: 2025-3-27 17:50 作者: chemical-peel 時間: 2025-3-28 00:33 作者: Vulnerary 時間: 2025-3-28 02:40
https://doi.org/10.1007/978-3-663-10474-2, dozens of clinical trials, and thousands of patients in registries, we know TNF to be a central cytokine mediating many chronic inflammatory diseases. We also know that therapeutic blockade of TNF is remarkably safe. Yet to be established are collateral benefits of treatment with TNF antagonists.作者: Hemodialysis 時間: 2025-3-28 09:23 作者: 周興旺 時間: 2025-3-28 11:43
Kinderarmut und soziale Ausgrenzung in Polenc dermatitis studies, important measures include the Eczema Area and Severity Index (EASI), the SCORAD, and the IGA. This chapter focuses on the most commonly used and the most psychometrically valid efficacy measures in clinical trials for psoriasis and eczema.作者: 富饒 時間: 2025-3-28 17:15
Kinderarmut in Ost- und Westdeutschlandeasurements of humanistic outcomes or clinical efficacy, such as utility scores, patient-reported outcomes, and number needed to treat. Finally, we present an example of a cost analysis for biologic agents in the treatment of psoriasis to emphasize the importance of pharmacoeconomic considerations in daily clinical practice for dermatologists.作者: 使成整體 時間: 2025-3-28 20:55
Kinderarmut in der WohlfahrtsgesellschaftIL-17A and other pro-inflammatory cytokines drive keratinocyte activation and hyperproliferation in psoriasis. This review will focus on the role of IL-23 in psoriasis pathogenesis and the therapeutic targeting of IL-23 by monoclonal antibodies in patients with psoriasis.作者: 性別 時間: 2025-3-28 22:57
Outcome Measures in Psoriasis and Atopic Eczema,c dermatitis studies, important measures include the Eczema Area and Severity Index (EASI), the SCORAD, and the IGA. This chapter focuses on the most commonly used and the most psychometrically valid efficacy measures in clinical trials for psoriasis and eczema.作者: 廢除 時間: 2025-3-29 03:31 作者: condemn 時間: 2025-3-29 07:55
Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis,IL-17A and other pro-inflammatory cytokines drive keratinocyte activation and hyperproliferation in psoriasis. This review will focus on the role of IL-23 in psoriasis pathogenesis and the therapeutic targeting of IL-23 by monoclonal antibodies in patients with psoriasis.作者: Immunization 時間: 2025-3-29 15:13
Book 2018the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders作者: 禁止,切斷 時間: 2025-3-29 15:40 作者: 水槽 時間: 2025-3-29 20:16 作者: Baffle 時間: 2025-3-30 01:52 作者: NAG 時間: 2025-3-30 04:16 作者: SCORE 時間: 2025-3-30 08:20 作者: Allergic 時間: 2025-3-30 15:59
nd biologic agents, as well as their clinical efficacy and s. .Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agen作者: Amenable 時間: 2025-3-30 20:18
Von der Nachkriegsnot zur Familienpolitik,logics. The chapter also discusses biosimilars and the complexity of their development and manufacturing along with highlighting the differences between two often-confused terms—biosimilarity and comparability.作者: 迷住 時間: 2025-3-30 22:36
Manufacturing of Biologics,logics. The chapter also discusses biosimilars and the complexity of their development and manufacturing along with highlighting the differences between two often-confused terms—biosimilarity and comparability.作者: Geyser 時間: 2025-3-31 01:47 作者: Biguanides 時間: 2025-3-31 08:56 作者: 表示問 時間: 2025-3-31 10:33
Interpreting Clinical Trial Data,nical trials directly impacts clinical decision making, which ultimately guides patient management (Page, Int J Sports Phys Ther 9: 726, 2014). The purpose of this chapter is to provide an overview of fundamental aspects of clinical trials, such as study designs, analyses, and methods of handling mi作者: 護(hù)航艦 時間: 2025-3-31 14:48 作者: Embolic-Stroke 時間: 2025-3-31 19:08
Quality of Life in the Dermatology Practice,ical functioning. The impact of these diseases on quality of life (QOL) can be significant, and the psychosocial impact of many dermatologic diseases is often more impactful than the physical appearance or symptoms alone. We now know that many chronic dermatologic conditions are more than skin deep,作者: 古董 時間: 2025-4-1 01:34
Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis,n reported and the warning labels have expanded. A variety of issues are now linked to biologic associated tumor necrosis factor-alpha (TNF-α) blocker use. Litigation has occurred with the use of a variety of biologics. The published risks of these agents include the development of lupus and autoimm作者: Grievance 時間: 2025-4-1 05:16
Patient and Physician Perspectives on Traditional Systemic and Biologic Therapies for Psoriasis,are safe, effective, convenient, accessible, and affordable. There are however a number of considerations from the perspectives of patients and providers which have the potential to present therapeutic dilemmas and barriers to patients achieving satisfaction in disease management. Herein we explore 作者: BRAWL 時間: 2025-4-1 09:14 作者: 外星人 時間: 2025-4-1 10:13
Pharmacovigilance,l are useful to determine short-term efficacy and side effects but with the relatively low numbers of patients may not provide realistic data on rare adverse events. In addition, a significant percentage of patients not eligible for clinical trials are placed on biologic therapy post-approval. Conti作者: 巫婆 時間: 2025-4-1 16:17 作者: 詼諧 時間: 2025-4-1 22:25
Immunogenicity of Biologic Agents in Psoriasis,xquisite specificity for their target. However, by their very nature of being proteins that are made externally to the patient, there is a risk that the patient’s immune system will develop an immune reaction to these medications. It is clear that immune reactions to medications, generally manifeste作者: circuit 時間: 2025-4-2 02:10 作者: atopic 時間: 2025-4-2 03:01
Tumor Necrosis Factor Inhibition,ter an initial, sputtering start in MS, septic shock, and congestive heart failure, clinical trials in rheumatoid arthritis established a development path in chronic inflammatory diseases. Plaque psoriasis was a serendipitous passenger on the psoriatic arthritis train. Over many years of development作者: 山間窄路 時間: 2025-4-2 08:25
